Tetratherix (ASX:TTX) has taken a significant step forward in the development of its prostate cancer technology, advancing its Tutelix spacer toward an international pivotal trial following encouraging early clinical results and the successful completion of a Series A capital raise by its joint venture partner. …
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 Australian Biotech
Latest Video
New Stories
-
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News